Genmab's multiple myeloma drug wins fast-track status

04/4/2013 | RTT News

The FDA granted fast-track status to daratumumab, an experimental multiple myeloma drug being developed by Genmab and Janssen Biotech. The designation covers patients who already received at least three lines of treatments including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a PI and an IMiD, this article says.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ